Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Loncar Cancer Immunotherapy ETF
(NQ:
CNCR
)
31.20
USD
-0.82 (-2.56%)
Official Closing Price
Updated: 4:00 PM EST, Feb 25, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Loncar Cancer Immunotherapy ETF
Loncar China BioPharma ETF (CHNA) Launches on Nasdaq
August 15, 2018
Loncar China BioPharma ETF (CHNA) launches on Nasdaq. CHNA offers exposure to leading companies in China’s burgeoning BioPharma industry.
From
Business Wire News Releases
Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management
February 16, 2018
Loncar Cancer Immunotherapy ETF (CNCR) surpasses $50 million in assets under management.
From
Business Wire News Releases
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
December 20, 2017
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance. Three Biotechnology Companies Added to the Index.
From
Business Wire News Releases
Loncar Cancer Immunotherapy Index Announces Merger Replacements
October 04, 2017
Loncar Cancer Immunotherapy Index Announces Merger Replacements. Gilead and NewLink Added to the Only Index that Tracks Cancer Immunotherapy.
From
Business Wire News Releases
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
June 21, 2017
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance. Three Biotechnology Companies Added to the Index.
From
Business Wire News Releases
Cancer Immunotherapy ETF (Nasdaq: CNCR) to Ring the Nasdaq Stock Market Opening Bell
October 28, 2016
From
GlobeNewswire News Releases
Cancer Immunotherapy ETF Celebrates One-Year Anniversary
October 14, 2016
The cancer immunotherapy ETF is celebrating its one-year anniversary. Cancer immunotherapy companies are beneficially disrupting status quo cancer treatments.
From
Business Wire News Releases
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
June 22, 2016
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance. Two New Immunotherapy Companies Added to the Index.
From
Business Wire News Releases
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
December 15, 2015
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
From
Business Wire News Releases
Loncar Investments Selects Cancer Research Institute as Exclusive Charitable Partner in Immunotherapy Research Donation Program
December 01, 2015
Loncar Investments Selects Cancer Research Institute as Exclusive Charitable Partner in Immunotherapy Research Donation Program
From
Business Wire News Releases
Market’s Only Cancer Immunotherapy ETF Launches
October 14, 2015
Market’s Only Cancer Immunotherapy ETF Launches; Exchange Traded Concepts Partners with Loncar Investments, ISE ETF Venture, and Amplify Development on the Loncar Cancer Immunotherapy ETF (CNCR)
From
Business Wire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.